Sainsburys Sleep Aid
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1. TRADE NAME OF THE MEDICINAL PRODUCT
Sleep Aid Tablets
Sleepeaze 25mg Tablets
Asda Sleep Aid Tablets
Numark Night Time Sleep Aid 25mg Tablets
Superdrug Sleep Aid 25mg Tablets
Morrisons Sleep Aid 25mg Tablets
Sainsbury’s Sleep Aid 25mg Tablets
Vantage Sleep Aid 25mg Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION Diphenhydramine Hydrochloride BP 25mg.
3 PHARMACEUTICAL FORM
Tablets for oral administration.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
A symptomatic aid to the relief of temporary sleep disturbance.
4.2 Posology and method of administration
Adults(including the elderly) and children over 16 years of age:
Two tablets (50 mg) twenty minutes before going to bed. Children under 16 years of age:
Not recommended for use.
4.3 Contraindications
Contra-indicated in patients who are hypersensitive to diphenhydramine or to any ingredients of the tablets, and in those with the following conditions: asthma, narrow angle glaucoma, prostatic hypertrophy, stenosing peptic ulcer, pyloroduodenal obstruction or bladder neck obstruction and porphyria.
4.4 Special warnings and precautions for use
Caution is required if administered to patients with hepatic disease.
Caution should be exercised in patients with glaucoma and urinary retention.
Should be used with caution in patients with myasthenia gravis or seizure disorders, bronchitis or chronic obstructive pulmonary disease (COPD).
Tolerance may develop with continuous use.
Side effects are more likely to occur in the elderly.
Patients with rare hereditary problems of galactose intolerance, the Lap lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Diphenhydramine may exacerbate tinnitus in existing tinnitus sufferers.
4.5 Interaction with other medicaments and other forms of interaction
Diphenhydramine has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquillizers and tricyclic antidepressants) resulting in increased antimuscarinic and sedative effects.
Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of Diphenhydramine. The product should be used with caution with monoamine oxidase inhibitors (MAOIs) or within 2 weeks of stopping an MAOI.
As Diphenhydramine has some antimuscarinic activity, the effects of antiocholinergic drugs (e.g. atropine, tricyclic antidepressants) may be potentiated therefore medical advice should be sought before taking Diphenhydramine with such medicines.
Diphenhydramine is an inhibitor of the cytochrome P450 isoenzyme CYP2D6. Therefore, there may be a potential for interaction with drugs which are primarily metabolised by CYP2D6, such as metoprolol and venlafaxine.
Diphenhydramine should not be used in patients receiving one of these drugs unless directed by a doctor.
4.6 Pregnancy and Lactation
Pregnancy
Risk benefit must be considered before administration in pregnancy. Diphenhydramine crosses the placental barrier and has been reported to cause jaundice and extrapyramidal symptoms in infants whose mothers received the drug during pregnancy.
Use of sedating antihistamines during the third trimester may result in reactions in the newborn or premature neonates. This drug is not recommended during pregnancy. Consult a doctor before use.
Lactation
If administered during breast feeding there is an increased risk of adverse effects of antihistamine, such as unusual excitation or irritability in infants.
Diphenhydramine hydrochloride is not recommended for use during lactation in nursing mothers. Consult a doctor before use.
4.7 Effects on ability to drive and use machines
Diphenhydramine has a major influence on the ability to drive and use machines. It is a hypnotic and will produce drowsiness or sedation soon after the dose has been taken.
Diphenhydramine may also cause dizziness, blurred vision, cognitive and psychomotor impairment. These can seriously affect the patient’s ability to drive and use machines. If affected do not drive or operate machinery.
The patient should be warned not to drive or operate machinery within 8 hours of ingestion.
4.8 Undesirable effects
Specific estimation of the frequency of adverse events for OTC products is inherently difficult (particularly numerator data). Adverse reactions which have been observed in clinical trials and which are considered to be common (occurring in> 1/100 to < 1/10) or very common (occurring in> 1/10) are listed below by MedDRA System Organ Class. The frequency of other adverse reactions identified during post-marketing use is unknown, but these reactions are likely to be uncommon (occurring in> 1/1,000 to <1/100) or rare (occurring in <
1/1,000).
General disorders and administration site conditions:
Common: fatigue
Immune system
disorders:
Unknown: Hypersensitivity reactions including rash, urticaria, dyspnoea and angioedema
Psychiatric disorders*:
Unknown: confusion, paradoxical excitation (e.g. increased energy, restlessness, nervousness)
* The elderly are more prone to confusion and paradoxical excitation. Nervous system disorders:
Common: sedation, drowsiness, disturbance in attention, unsteadiness, dizziness, Unknown: convulsions, headache, paraesthesia, dyskinesias
Eye disorders:
Unknown: blurred vision
Ear and labyrinth disorders: Unknown: tinnitus
Cardiac disorders:
Unknown: tachycardia, palpitations Respiratory, thoracic and mediastinal disorders: Unknown: thickening of bronchial secretions Gastrointestinal disorders:
Common: dry mouth
Unknown: gastrointestinal disturbance including nausea, vomiting Musculoskeletal and connective tissue disorders: Unknown: muscle twitching Renal and urinary disorders:
Unknown: urinary difficulty, urinary retention Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
4.9 Overdose
Overdose is likely to result in effects similar to those listed under adverse reactions.
Additional symptoms may include mydriasis, fever, flushing, agitation, tremor, dystonic reactions, hallucinations and ECG changes. Large overdose may cause rhabdomyolysis, convulsions, delirium, toxic psychosis, arrhythmias, coma and cardiovascular collapse.
Treatment should be supportive and directed towards specific symptoms. Convulsions and marked CNS stimulation should be treated with parenteral diazepam.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Diphenhydramine hydrochloride has anti-histaminic (H1- receptor), anti-emetic, anti-vertigo and sedative and hypnotic properties.
Anti-histamine action occurs by blocking the spasmogenic and congestive effects of histamine by competing with histamine for H1 receptor sites on effector cells, preventing but not reversing responses mediated by histamine alone.
Anti-emetic action is by inhibition in medullary chemoreceptor trigger zone.
Anti-vertigo action is by central antimuscarinic effect on the vestibular apparatus and the integrative vomiting centre and medullary chemoreceptor trigger zone of the mid brain.
The exact mechanism for CNS depressant action is not known, but it is thought to cause indirect reduction of stimuli to the brain stem reticular formation.
5.2 Pharmacokinetic properties
Following oral administration, the drug is well absorbed from gastro-intestinal tract. It is highly bound to plasma proteins and is metabolised by the liver. Onset of action is 20 minutes and duration of effect being 4-6 hours. It is eliminated by the kidneys slowly, mainly as inactive as metabolites.
5.3 Preclinical safety data
There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Lactose BP
Maize starch BP Magnesium stearate BP
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
3 years in tablet containers. 3 years in blister packs.
6.4 Special precautions for storage
Blister packaging - Do not store above 250C. Store in the original package. Keep container in outer carton.
Tablet containers - Do not store above 250C. Store in original container. Keep the container tightly closed.
6.5 Nature and contents of container
Polypropylene containers with polyethylene child resistant closures, containing 20 tablets.
Blister strips comprised of 20pm aluminium foil 250pm/PVC enclosed in a carton containing 6, 8, 10, 12, 16, or 20 tablets.
Aluminium /PVC/PVDC blister strips enclosed in a cardboard outer containing 6, 8, 10, 12, 16, or 20 tablets.
6.6 Special precautions for disposal
Not applicable.
7 MARKETING AUTHORISATION HOLDER
Galpharm Healthcare Limited Wrafton,
Braunton,
Devon,
EX33 2DL,
United Kingdom.
8 MARKETING AUTHORISATION NUMBER(S)
PL 16028/0014
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 23rd September 1997
10 DATE OF REVISION OF THE TEXT
05/09/2014